GoodRx (NASDAQ:GDRX) Hits New 12-Month Low - Should You Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price hit a new 52-week low during trading on Friday . The stock traded as low as $4.04 and last traded at $4.04, with a volume of 266677 shares changing hands. The stock had previously closed at $4.29.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wells Fargo & Company cut their target price on GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Morgan Stanley cut their price objective on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Citigroup reduced their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Finally, KeyCorp dropped their target price on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $8.18.

GoodRx Trading Up 14.7 %

The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock's 50 day moving average is $4.68 and its 200-day moving average is $5.12. The company has a market cap of $1.80 billion, a PE ratio of -156.33, a P/E/G ratio of 2.46 and a beta of 1.25.

Remove Ads

Institutional Trading of GoodRx

Hedge funds have recently made changes to their positions in the business. National Bank of Canada FI increased its stake in GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares during the last quarter. Gotham Asset Management LLC boosted its holdings in shares of GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company's stock worth $82,000 after purchasing an additional 4,182 shares during the period. Gagnon Securities LLC increased its position in shares of GoodRx by 9.9% during the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock valued at $325,000 after purchasing an additional 6,266 shares during the last quarter. Swiss National Bank raised its holdings in GoodRx by 4.1% during the 4th quarter. Swiss National Bank now owns 161,400 shares of the company's stock valued at $751,000 after buying an additional 6,400 shares during the period. Finally, Fortem Financial Group LLC boosted its stake in GoodRx by 7.2% during the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company's stock worth $554,000 after buying an additional 7,996 shares during the period. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.